Home > Insider Trading > Filing (0001104659-16-139254)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1638287	Gemphire Therapeutics Inc.	GEMP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1381030	Phd Charles Bisgaier	43334 Seven Mile Road Suite 1000 Northville MI 48167	Chair & Chief Scientific Off.	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-10	59,561	$0.00	59,561	No	4	C	Indirect	Held by The Charles L. Bisgaier Trust
Common Stock	Acquisiton	2016-08-10	6,515	$6.71	66,076	No	4	J	Indirect	Held by The Charles L. Bisgaier Trust
Common Stock	Acquisiton	2016-08-10	16,144	$6.71	82,220	No	4	C	Indirect	Held by The Charles L. Bisgaier Trust
Common Stock	Acquisiton	2016-08-10	19,228	$6.71	19,228	No	4	C	Indirect	Held by Bisgaier Family, LLC
Common Stock	Acquisiton	2016-08-10	51,750	$10.00	1,244,440	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Held by The Charles L. Bisgaier Trust
No	4	J	Indirect	Held by The Charles L. Bisgaier Trust
No	4	C	Indirect	Held by The Charles L. Bisgaier Trust
No	4	C	Indirect	Held by Bisgaier Family, LLC
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2016-08-10	59,561	$0.00	59,561	$0.00
Common Stock	8% Convertible Subordinated Promissory Notes	Disposition	2016-08-10	0	$0.00	16,144	$6.71
Common Stock	8% Convertible Subordinated Promissory Notes	Disposition	2016-08-10	0	$0.00	19,228	$6.71

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
These shares are indirectly owned by the reporting person as trustee of The Charles L. Bisgaier Trust.
Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
The notes were issued in the original principal amount of $100,000. The outstanding principal and $8,263 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.
The notes were issued in the original principal amount of $125,000. The outstanding principal and $3,945 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.